This week, the Department of Health and Human Services (HHS) took significant steps against the controversial child sex reassignment industry, which has faced scrutiny since a presidential order from Donald Trump on January 28 directed federal agencies to eliminate practices deemed harmful, including chemical and surgical procedures on children.
The HHS has put forth a comprehensive report that challenges the narratives often promoted by LGBT advocates regarding “gender-affirming care.” It stresses that the negative consequences of treatments like puberty blockers and cross-sex hormones are substantial and frequently overlooked by many in the medical community.
“Today marks a new direction for HHS and our country,” said HHS Assistant Secretary Brian Christine in a statement to Blaze News, crediting the report’s release to efforts from President Trump and Secretary Robert F. Kennedy Jr.
A 410-page document titled “Treatment of Childhood Gender Identity Disorder: A Review of Evidence and Best Practices,” is a U.S. counterpart to the UK’s Cass Review. The report outlines that:
- The potential dangers and uncertainties around puberty blockers and surgeries are often ignored.
- Guidelines from the World Professional Association for Transgender Health sometimes lack scientific backing.
- There are ethical dilemmas regarding consent and the widespread regret expressed by individuals who have undergone these procedures.
- Many countries are moving away from “gender-affirming” care models.
Dr. Jay Bhattacharyya, from the National Institutes of Health, described the report as transformative for American medicine. It indicated that the existing evidence about the long-term effects of gender transition is of “very low” quality.
This suggests that the positive outcomes often cited by proponents of gender reassignment may not align with reality. The document further highlights numerous risks commonly associated with such procedures, including infertility and various psychological and physical disorders, while acknowledging that existing research might not accurately reflect these dangers.
It states that many medical professionals are neglecting their responsibilities to prioritize the welfare of young patients, pointing out the rapid adoption of clinical protocols that lack strong justifications. Critics have voiced concerns that alternative, contradictory evidence has been dismissed or misrepresented.
Secretary Kennedy stated that certain authoritative medical organizations have perpetuated the belief that these procedures are beneficial for children, arguing that they have betrayed their foundational commitment to do no harm, resulting in lasting damage to vulnerable youth.
As several countries, especially the UK, reevaluate their strategies for dealing with gender dysphoria, the U.S. administration appears to be intensifying its push for child gender reassignment. Notably, Rachel Levine, a prominent figure in HHS, has faced criticism for allegedly implementing politically motivated changes to age guidelines for procedures.
Christine emphasized that this billion-dollar industry generates ongoing “customers” through repeated interventions, revealing a cycle where initial treatments lead to further medical complications.
Neeraja Deshpande from the Independent Women’s Forum remarked that the report reinforces concerns regarding surgical interventions under the guise of gender reassignment, reinforcing the need for medical transparency and accountability.
Terry Schilling, president of the American Principles Project, noted that the report could fundamentally change the landscape of children’s healthcare regarding gender reassignment, suggesting the potential for significant legal repercussions against the industry.
As lawsuits, like that of Chloe Cole—a detransitioned individual suing for medical negligence—gain traction, the narrative surrounding these medical interventions continues to evolve. Christine expressed hope that the report would lead to lasting changes, emphasizing the administration’s commitment to safeguarding children and ensuring high-quality scientific standards.
